Recent

% | $
Quotes you view appear here for quick access.

Intercept Pharmaceuticals, Inc. Message Board

vvusforme71 3 posts  |  Last Activity: May 11, 2015 7:41 PM Member since: Sep 6, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    The Street says SELL

    by feetyme May 11, 2015 4:34 PM
    vvusforme71 vvusforme71 May 11, 2015 7:41 PM Flag

    Needham & Company affirms Intercept Pharma (NASDAQ: ICPT) with a Buy rating and $500 price target following Q1 results issued Monday morning.

    Ahead of the opening bell, Intercept reported Q1 EPS of ($1.78) and revenue of $405,000, versus the analyst EPS estimate of ($1.69) and revenue of $1.7 million.

    Analyst Alan Carr commented, “The company plans to complete Obeticholic Acid (OCA) rolling NDA submission in Primary Biliary Cirrhosis (PBC) in 2Q15. MAA submission is also on track for this quarter. We expect commercial launch in U.S. in early 2016, followed by E.U. later next year (unch). We continue to expect initiation of OCA Phase 3 development in NASH around mid-2015, although discussions w/FDA and EMA are still underway.”

    “Intercept ended 1Q15 with $402.0M in cash, up from $239.7 million at YE15. This includes $191.6 million in net proceeds from a public offering in Feb 2015, but excludes $366.8 million in net proceeds from an Apr 2015 public offering. Mgmt guided for 2015 cash burn of $180 - $200 million,” the analyst noted

  • Reply to

    Soon many upgrades coming and no shares to buy

    by djisgreat1951 May 11, 2015 12:17 PM
    vvusforme71 vvusforme71 May 11, 2015 7:41 PM Flag

    Needham & Company affirms Intercept Pharma (NASDAQ: ICPT) with a Buy rating and $500 price target following Q1 results issued Monday morning.

    Ahead of the opening bell, Intercept reported Q1 EPS of ($1.78) and revenue of $405,000, versus the analyst EPS estimate of ($1.69) and revenue of $1.7 million.

    Analyst Alan Carr commented, “The company plans to complete Obeticholic Acid (OCA) rolling NDA submission in Primary Biliary Cirrhosis (PBC) in 2Q15. MAA submission is also on track for this quarter. We expect commercial launch in U.S. in early 2016, followed by E.U. later next year (unch). We continue to expect initiation of OCA Phase 3 development in NASH around mid-2015, although discussions w/FDA and EMA are still underway.”

    “Intercept ended 1Q15 with $402.0M in cash, up from $239.7 million at YE15. This includes $191.6 million in net proceeds from a public offering in Feb 2015, but excludes $366.8 million in net proceeds from an Apr 2015 public offering. Mgmt guided for 2015 cash burn of $180 - $200 million,” the analyst noted

  • you will just wake up one morning and it will be double its closing value.

ICPT
241.17+3.94(+1.66%)Jul 2 4:00 PMEDT